STATEMENT - Science on BPA and Link to Human Health Impacts

[Print Version]

 

If Governor Paul LePage really looked at the science, he’d see serious concern about the effects of BPA on children’s health.  We refer the Governor to the authoritative conclusions of the top scientists in the country at the Maine Center for Disease Control and Prevention, the Endocrine Society and several US government agencies:

The Science on BPA (or bisphenol A)

Maine Center for Disease Control and Prevention (2010):

“There is no controversy that BPA is an endocrine disruptor, acting by inhibiting the effects of estrogen, a vital reproductive and developmental hormone. … The current consensus of most scientists, as well as U.S. and international government agencies, is that there is sufficient evidence that BPA produces adverse effects at environmentally relevant exposures. Well over 100 studies have documented adverse effects on growth, brain development, behavior, early onset of puberty, changes in sex hormones, male fertility, and immune function as a result of exposure to environmentally relevant doses during the prenatal or postnatal period in animal models.”

Dr. Deborah Rice, Maine CDC toxicologist: Rationale for Concurrence by Maine Center for Disease Control and Prevention on the Designation of Bisphenol A as a Priority Chemical. April 23, 2010.

 

U.S. Department of Health and Human Services (2008):

“The NTP [National Toxicology Program] has some concern for effects on the brain, behavior, and prostate gland in fetuses, infants and children at current human exposures to bisphenol A.”

National Toxicology Program (NTP), Center for the Evaluation of Risks to Human Reproduction (CERHR). NTP-CERHR monograph on the potential human reproductive and developmental effects of bisphenol A. September 2008. NIH publication number 08-5994.

 

U.S. Center for Disease Control and Prevention (2008):

“Our data suggest that exposure to BPA in the United States is widespread.” An ongoing study, which collects data representative of the U.S. population, found BPA in 93% of all individuals, with BPA levels in children 6-11 years of age almost twice as high as adults (younger children were not sampled).

Calafat, A.M., Ye, X., Wong, L-Y., Riedy, J.A., and Needham, L. Exposure to the U.S. population to bisphenol A and 4-tertiary-octophenol: 2003-2004. Environmental Health Perspectives 116(1):39-44 (2008).

 

U.S. Food and Drug Administration (2010):

“FDA shares the perspective of the National Toxicology Program that recent studies provide reason for some concern about the potential effects of BPA on the brain, behavior, and prostate gland of fetuses, infants and children. … FDA supports reasonable steps to reduce exposure of infants to BPA in the food supply.”

Update on bisphenol A for use in food contact applications: January 2010.

 

U.S. Environmental Protection Agency (2010):

“EPA will consider whether further action is needed to address human health risks resulting from non-food-packaging uses of BPA. … EPA has jurisdiction over environmental exposures to BPA … (which) may present an unreasonable risk of injury to the environment on the basis of its potential for long-term adverse effects on growth, reproduction and development in aquatic species at concentrations similar to those found in the environment.”

Bisphenol A Action Plan. March 29, 2010.

 

The Endocrine Society (2009):

“These results indicate that perinatal exposure to environmentally relevant doses of BPA results in persistent alterations in mammary gland morphogenesis, development of precancerous lesions, and carcinoma in situ.… these findings indicate that BPA may “imprint” the prostate through epigenetic modifications, resulting in predisposition to carcinogenesis.”

The Endocrine Society is a professional association whose mission is “To advance excellence in endocrinology and promote its essential role as an integrative force in scientific research and medical practice.”

Diamanti-Kandarakis E et al. 2009 Endocrine-Disrupting Chemicals: An Endocrine Society Scientific Statement, Endocrine Reviews 30(4):293-342.